World-class liquid biopsy testing will be made
commercially available to BioReference® customers across the
country
BOSTON and ELMWOOD
PARK, N.J., and ROLLE, Switzerland, Nov. 7, 2023
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
software company and a leader in data-driven medicine, today
announced that BioReference® Health, LLC, an OPKO Health, Inc.
company and full-service laboratory that processes more than 12
million tests annually, will implement SOPHiA GENETICS' technology
and add MSK-ACCESS® liquid biopsy to its test suite. With
the implementation of SOPHiA GENETICS, BioReference will be the
first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA
DDM™. The offering will be commercially available for ordering by
healthcare providers through BioReference, and its specialty
division, GenPath® Oncology in 2024.
Since January 2023, Memorial Sloan
Kettering Cancer Center (MSK) and SOPHiA GENETICS have been working
on merging MSK-ACCESS® technology with the SOPHiA DDM™ Platform
algorithms to provide a comprehensive liquid biopsy assay
available on the decentralized platform. The new
offering takes advantage of the sophisticated analytics of the
SOPHiA DDM™ Platform, combining its state-of-the-art algorithms and
global network with the scientific and clinical expertise of MSK in
cancer genomics. The onboarding of BioReference aims to bring
access to world-class liquid biopsy testing to the laboratory's
customers across the country.
"The availability of MSK-ACCESS® powered with SOPHiA
DDM™ will support pioneer laboratories like
BioReference taking their genomic analysis capabilities to the next
level, by enhancing their ability to serve their customers with a
cutting-edge liquid biopsy assay," said Philippe Menu, M.D., PhD.,
Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. "We are eager to begin
implementation with BioReference and help bring this critical
cancer testing technology to more areas throughout the U.S.,
including rural and underserved populations."
BioReference currently operates 10 laboratory facilities across
the U.S. and provides scientific expertise in oncology, urology,
and women's health. The laboratory's oncology division, GenPath
Oncology, offers a comprehensive portfolio to support the continuum
of care of cancer patients – from risk assessment to treatment
planning. Deploying in-house liquid biopsy testing will enable the
laboratory to analyze samples from a simple, non-invasive blood
draw, allowing for less invasive monitoring of cancers. The
offering will incorporate SOPHiA GENETICS' advanced genomic
analysis, made possible with artificial intelligence (AI), and
expedited streamlined insights to increase the ability of clinician
researchers to practice precision medicine.
"We're proud to be the first commercial laboratory to be able to
offer this liquid-based technology," said Ellen Beausang, Chief Commercial Officer,
BioReference. "The adoption of the SOPHiA GENETICS platform along
with MSK's oncology genomics technology signals our ongoing and
unwavering commitment to improving cancer care for patients, and
offering advanced tools and solutions that empower timely and
critical decision-making for healthcare providers and patient
outcomes."
MSK-ACCESS® powered with SOPHiA DDM™ is being designed to
align with the most up-to-date guidelines and clinical trial data,
reflecting major biologically actionable biomarkers. In addition to
quickly providing analysis and insights, the SOPHiA DDM™ Platform
will allow BioReference to retain ownership of its database and
obtain reproducible data that can help accelerate future work.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect on X,
LinkedIn, Facebook, and Instagram.
For more information on BioReference, visit
https://www.bioreference.com/, or connect on LinkedIn, Instagram,
Facebook and X.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
About BioReference Health, LLC
BioReference® Health LLC, an OPKO Health, Inc. Company (NASDAQ:
OPK), empowers confident healthcare decisions by prioritizing
service, creating innovative solutions, and offering scientific
expertise in oncology, urology, and women's health.
Headquartered in Elmwood Park, New
Jersey, BioReference operates 10 laboratory facilities
around the country, is in-network with the largest health plans in
the United States and processes
more than 12 million tests annually. BioReference
provides credible and tailored solutions for a variety of
customers and patients, including medical practices small and
large, hospitals and health systems, correctional institutions,
government agencies, educational systems, and sport leagues. In
addition to an extensive test menu with 99 percent of tests
performed in-house, BioReference's differentiated offerings include
large-scale health screening programs, on-demand mobile phlebotomy,
and transformative business solutions that optimize laboratory
management. For more information visit
https://www.bioreference.com/.
MSK-ACCESS® powered with SOPHiA DDM™ is a product in
development and may not be available for sale. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bioreference-signs-on-as-the-first-laboratory-to-use-msk-access-powered-with-sophia-ddm-301979640.html
SOURCE SOPHiA GENETICS